Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Change in PDL Status for the Macrolides-Ketolides Drug Class Effective November 7, 2023

Last updated on

In response to the shortage of the preferred brand name product Eryped 200 MG/5 ML suspension, the Texas Health and Human Services Commission (HHSC) has removed the non-preferred status from the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension products on the preferred drug list (PDL).

Note: The preferred status of the brand name Eryped 200 MG/5 ML suspension with National Drug Code (NDC) 24338013213 will not change so that any existing stock may be used.

Effective November 7, 2023, HHSC removed the non-preferred status of the following products to allow providers to prescribe generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension without requiring a PDL prior authorization. This allows clients to continue accessing the necessary medication.

The table below lists the erythromycin products with their NDCs.

NDCDrug Name
62559044001Erythromycin 200 MG/5 ML Suspension
62559044002Erythromycin 200 MG/5 ML Suspension
62559063001Erythromycin 200 MG/5 ML Suspension
69238150301Erythromycin 200 MG/5 ML Suspension
75834029501Erythromycin 200 MG/5 ML Suspension
24338013402E.E.S. 200 MG/5 ML Suspension
24338013610E.E.S. 200 MG/5 ML Suspension

Email vdp-formulary@hhsc.state.tx.us with comments or questions.